Your search found 2 Results
BMJ Sexual and Reproductive Health. 2018 Jan; 44(1):66-68.Following publication of the author's trial on the effects of postnatal depot medroxyprogesterone acetate (DMPA) compared with the copper intrauterine device (IUD) on postnatal depression in this journal in July 2016, they have sought to evaluate contraceptive discontinuation in our study sample. Postnatal contraception is promoted as part of the WHO strategy to reduce the unmet need for family planning in low- and middle-income countries (LMICs) and to reduce preventable maternal and child mortality. However, little is known about discontinuation rates associated with postnatal contraception use in these settings. From the trial, 75 of 242 participants were contactable two or more years after randomisation and 54 consented to a follow-up interview, which was conducted by a Masters student from the University of Fort Hare (NDY). Twenty-three women had received DMPA and 31 women an IUD. In the DMPA and IUD arms, respectively, 48% (11/23) and 42% (13/31) had discontinued their contraceptive methods by the time of the interview. All participants who discontinued did so within the first year, 10 within 3 months of allocation (DMPA=4, IUD=6), and 17 within 6 months (DMPA=7, IUD=10). Six of the participants allocated to DMPA (26%) and five allocated to the IUD (16%) became pregnant following discontinuation.
International Planned Parenthood Federation adds Norplant implants to its commodities list of approved contraceptives. News release.
New York, New York, Population Council, 1985 Oct 5. 3 p.On December 5, 1985, the Population Council announced that the International Planned Parenthood Federation (IPPF) has approved the inclusion of Norplant implants on its commodities list of contraceptives available to its affiliates. This action means that the Norplant method will be available to the 120 IPPF-affiliated national family planning associations once the contraceptive has been approved for distribution by regulatory authorities in each country. IPPF has indicated that it will supply the implants to agencies that: 1) have a sufficient number of health workers who have been formally trained in Norplant insertion, removal, and counseling techniques; 2) have suitable clinic facilities and adequate back-up and referral systems; and 3) can arrange training so that additional health workers will qualify to use this method. The Norplant method was approved by the IPPF Advisory Panel on September 8, 1985, following an 18-month period of review of all available scientific data. The Norplant system has been used in clinical trials in 25 countries involving over 25,000 acceptors. The Population Council has cited the inclusion of Norplant implants in the IPPF program as an important step in the worldwide availability of this contraceptive method. The Population Council has established regional training centers in Indonesia, Egypt, Chile, Brazil, and the Dominican Republic where health care personnel can be trained in techniques of insertion and removal of the impants as well as in counseling potential acceptors.